Biocept to Present at the 29th Annual ROTH Conference

SAN DIEGO, March 8, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 29^th Annual ROTH Conference on Monday, March 13, 2017, at 8:00 a.m. Pacific time (11:00 a.m. Eastern time).  The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif. 

A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. A replay of the presentations will be available for 90 days.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA).  With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-29th-annual-roth-conference-300418044.html

SOURCE Biocept, Inc.